Omada Health financials
$19.37−0.10%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 |
|---|---|---|---|---|---|
| Revenue | $87.8M | $78.0M | $75.8M | $68.0M | $61.4M |
| Gross profit | $63.8M | $48.7M | $53.7M | $45.1M | $40.3M |
| Gross margin | 72.6% | 62.4% | 70.8% | 66.3% | 65.7% |
| Operating income | $3.5M | -$4.8M | $3.3M | -$2.5M | -$4.3M |
| Net income | $5.3M | -$3.0M | $5.2M | -$3.2M | -$5.3M |
| Net margin | 6.0% | −3.8% | 6.8% | −4.7% | −8.7% |
| Diluted EPS | $0.08 | $-0.05 | $0.09 | $-0.06 | $-0.24 |
| EBITDA | $5.1M | -$3.3M | $4.7M | -$1.2M | -$3.0M |
| Operating cash flow | $4.0M | -$11.8M | $21.4M | $10.1M | $2.9M |
| Free cash flow | $3.9M | -$11.9M | $21.2M | $9.6M | $2.6M |
| Diluted shares | 63.9M | 58.9M | 58.7M | 57.7M | 22.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 |
|---|---|---|---|---|---|
| Cash & equivalents | $221.7M | $211.8M | $222.0M | $198.6M | $223.1M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $30.0M |
| Total assets | $328.2M | $302.8M | $305.4M | $287.5M | $303.0M |
| Total liabilities | $75.5M | $68.7M | $75.7M | $70.1M | $88.8M |
| Shareholders' equity | $252.7M | $234.1M | $229.7M | $217.3M | $214.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology